nice3 Jan 2019 19:10
From the AGM posted on ADVFN
Q: Can you tell us about the competitor programs for SDC-1801 and SDC-1802?
A: For SDC-1801 the main competitors with TYK2/JAK1 inhibitors are Pfizer and BMS (both just starting phase III), Nimbus also who have a drug in preclinical. For SDC-1802, there is one JAK1 inhibitor (without TYK2 activity) recently approved. Our SDC-1802 is predominantly a TIK2 inhibitor with some JAK1 activity